Analgesic nephropathy and urothelial carcinoma.
D000700:Analgesics / Q000009:adverse effects*; D001241:Aspirin / Q000009:adverse effects; D002110:Caffeine / Q000009:adverse effects; D002295:Carcinoma, Transitional Cell / Q000139:chemically induced*; D003061:Codeine / Q000009:adverse effects; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000139:chemically induced*; D007682:Kidney Pelvis / Q000187:drug effects; D008297:Male; D009395:Nephritis, Interstitial / Q000139:chemically induced*; D010615:Phenacetin / Q000009:adverse effects; D001749:Urinary Bladder Neoplasms / Q000139:chemically induced*
D000700:Analgesics; D002110:Caffeine; D010615:Phenacetin; D001241:Aspirin; D003061:Codeine